MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/03/6406-1485-1493$20.00
Mol Pharmacol 64:1485-1493, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davidson, T.
Right arrow Articles by Costa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davidson, T.
Right arrow Articles by Costa, M.

Hypoxia Inducible Factor-1{alpha}-Independent Suppression of Aryl Hydrocarbon Receptor-Regulated Genes by Nickel

Todd Davidson, Konstantin Salnikow, and Max Costa

Nelson Institute of Environmental Medicine, New York University School of Medicine, New York, New York

Aryl hydrocarbon receptor (AhR)-dependent enzymes are involved in the biotransformation of harmful xenobiotics into more easily excretable metabolites. Cross-talk between the AhR pathway and the hypoxia inducible factor-1{alpha} (HIF-1{alpha}) pathway has been demonstrated previously, although the mechanism remains unclear and quite controversial. Because nickel is known to mimic hypoxia, we investigated the effects of short-term nickel exposure on AhR-dependent gene expression. Gene-chip analysis identified several AhR-dependent genes that are suppressed by exposure to nickel. Using Northern blots, we then confirmed that nickel can down-regulate both the basal and benzo[a]pyrene-inducible expression of AhR-dependent genes in mouse and human cell lines. Using a HIF-1{alpha} knockout cell line and 3-[2-[4-(bis-(4-fluorophenyl) methylene]-1-piperidinyl)ethyl]-2,3-dihydro-2-thioxo-4(1H)quinazolinone (R59949), which blocks HIF-1{alpha} protein accumulation, we show HIF-1{alpha}-independent suppression of AhR-dependent genes by nickel. Desferrioxamine and hypoxia were also able to suppress the basal and inducible expression levels of AhR-regulated genes. Finally, dimethyloxalylglycine, an inhibitor of Fe(II)- and 2-oxoglutarate-dependent dioxygenases also inhibited AhR-dependent expression in a HIF-1{alpha}-independent manner. Our data suggest that an Fe(II)-, oxoglutarate-, and oxygen-dependent enzyme may directly or indirectly be involved in the regulation of AhR-dependent transcriptional activity by nickel and other hypoxia-mimicking agents.


Received May 5, 2003; accepted August 28, 2003

Address correspondence to: Todd Davidson, 57 Old Forge Road, Tuxedo, NY 10987. E-mail: davidson{at}env.med.nyu.edu




This article has been cited by other articles:


Home page
CarcinogenesisHome page
Q. Ke, Q. Li, T. P. Ellen, H. Sun, and M. Costa
Nickel compounds induce phosphorylation of histone H3 at serine 10 by activating JNK-MAPK pathway
Carcinogenesis, June 1, 2008; 29(6): 1276 - 1281.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
H. Chen and M. Costa
Effect of soluble nickel on cellular energy metabolism in a549 cells.
Experimental Biology and Medicine, October 1, 2006; 231(9): 1474 - 1480.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Franco, S. Man, L. Chen, U. Emmenegger, Y. Shaked, A. M. Cheung, A. S. Brown, D. J. Hicklin, F. S. Foster, and R. S. Kerbel
Targeted Anti-Vascular Endothelial Growth Factor Receptor-2 Therapy Leads to Short-term and Long-term Impairment of Vascular Function and Increase in Tumor Hypoxia.
Cancer Res., April 1, 2006; 66(7): 3639 - 3648.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics